• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Drugmakers Pledge Science over Speed in Vaccine Trials

Drugmakers Pledge Science over Speed in Vaccine Trials

September 14, 2020

The CEOs of nine pharmaceutical companies racing to develop COVID-19 vaccines made an unprecedented pledge last week to “uphold the integrity of the scientific process” in the trials they are conducting for vaccine approval.

The unusual move was meant to ease the public’s doubts about the process used to evaluate and approve COVID-19 vaccines and comes as the push for a COVID-19 vaccine by year’s end heats up, with President Trump vowing last week that a vaccine approval could come as early as October.

The safety pledge came from CEOs at AstraZeneca, Pfizer, BioNTech, GlaxoSmithKline, Johnson & Johnson, Merck, Moderna, Novavax and Sanofi. Four of the companies, AstraZeneca, Moderna and Pfizer/BioNTech jointly, already have three vaccine candidates in phase 3 trials.

All of the companies pledged that they will only file for approval or Emergency Use Authorization for their vaccines after they have demonstrated safety and efficacy in a phase 3 trial. They also pledged to maintain “high scientific and ethical standards” in clinical trials and the manufacture of the vaccines, and to make the safety and well-being of vaccinated individuals their top priority.

Multiple polls have found that Americans are largely skeptical of the accelerated COVID-19 vaccine development process and believe that the Trump administration is pressuring the FDA to approve a vaccine before safety and efficacy thresholds have been met.

COVID-19
  • Related Directories

    Veklury (remdesivir)

    Comirnaty (COVID-19 Vaccine, mRNA)

    Spikevax, COVID-19 Vaccine (mRNA-1273)

Upcoming Events

  • 17May

    Three Data Trends to Consider Now When Developing Your Decentralized Clinical Trial Strategy

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing